Whether capivasertib tablets (capivasertib) has been included in the medical insurance and reimbursement policy

Capisetinib is an oral AKT inhibitor, mainly used to treat patients with breast cancer and some solid tumors carrying PIK3CA gene mutations. The drug interferes with the proliferation and survival of tumor cells by inhibiting the AKT signaling pathway, thereby exerting anti-tumor effects. Due to its strong targeting and oral convenience, it has become a new choice for some patients with advanced breast cancer.

In the domestic market, Carpisete tablets have been officially launched and are currently covered by medical insurance, and patients need to purchase them at their own expense. The specific price and reimbursement policy have not yet been clarified and will be determined based on the supply of drugs and subsequent policy updates from local medical insurance bureaus. Clinically, when prescribing Carpizote tablets, doctors will reasonably evaluate the medication plan based on the patient's genetic test results, previous treatment history and economic conditions.

In foreign markets, the original drug capositinib has been launched in Europe, the United States and Switzerland. The common specification is 200mg*64 tablets. The price per box is about more than 60,000 yuan, which is relatively high. For some patients, cost pressure is greater, but drug efficacy and clinical data support its reliability in targeted therapy. Overseas purchases usually need to go through formal medical institutions or pharmacies and follow prescription drug management regulations.

In addition, there are already generic drugs of the Lao Lucius version in the overseas market. The specifications are the same as the original drug. The price per box is about more than 3,000 yuan, and the drug ingredients are basically the same as the original drug. Although cheap, a doctor still needs to evaluate suitability and dosage regimen before use.

Reference materials:https://en.wikipedia.org/wiki/Isatuximab